Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

Denali Therapeutics Inc. (NASDAQ:DNLI) is advancing a drug by the name of DNL-310 [tividenofusp alfa] for the treatment of patients with MSP II [Hunter Syndrome]. It had been able to report positive results from an ongoing phase 1/2 study, using this drug to treat these patients, at the 20th Annual WORLD Symposium. In essence, this highlights positive two-year data that patients achieved improvements in terms of both biomarkers and other clinical outcome measures. This lead program sets about two major reas ...